Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.
Glumetinib (SCC 244) displays high selectivity versus 312 other tested protein kinases.
Glumetinib (SCC 244) profoundly and specifically inhibits c-Met signal transduction and suppresses the c-Met-dependent neoplastic phenotype of tumor and endothelial cells.
Glumetinib (SCC 244) exhibits robust in vivo antitumor activity in NSCLC and hepatocellular carcinoma models.
